NEWSER) – First, the esteemed Lancet medical journal retracted a major study on Thursday about hydroxychloroquine. Then, the New England Journal of Medicine did the same with another big study related to COVID-19 and blood pressure drugs. Both retractions have a common denominator: They relied on data supplied by a US analytics company called Surgisphere, which is coming under increasing scrutiny over the credibility of its international database. The Lancet study had cast doubt on the effectiveness of the anti-malarial drugs hydroxychloroquine and chloroquine as a coronavirus treatment, reports the Wall Street Journal. The retraction is now renewing the hope that the drugs (highly touted by President Trump) can work safely after all, and the World Health Organization already has said it would resume trials, notes the New York Times.